Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion

What happened

Merck on Monday announced a global licensing agreement with China's SciBrunch Therapeutics worth up to $2.13 billion for an experimental cancer treatment. This deal is Merck's latest in a series of business development moves aimed at bolstering its oncology pipeline ahead of Keytruda's expected loss of exclusivity in 2028-2029. Compared to previous deals like the $10.4B Verona acquisition and $9.2B Cidara acquisition, this licensing agreement is relatively small but still broadens Merck's cancer drug portfolio. The master report highlighted Merck's need to establish multiple new revenue pillars by 2027 to offset the Keytruda decline; this deal contributes incrementally but is unlikely to materially change the near-term financial outlook. Merck's current WAIT rating reflects the need for evidence of successful diversification and China Gardasil recovery, and this licensing deal does not alter that fundamental thesis.

Implication

Investors should view this as part of Merck's ongoing effort to de-risk its Keytruda concentration, but the financial impact is limited given the size relative to Merck's revenue. The deal could provide long-term growth optionality if the drug succeeds, but near-term catalysts remain focused on Gardasil China shipments and the FY2026 headwind of ~$2.5B. Merck's balance sheet can absorb such deals without strain, but the recurring theme of large BD indicates management's lack of confidence in organic pipeline sufficiency. Until there is clearer visibility on new launch performance and China vaccine recovery, the stock is likely to remain rangebound. The rating remains WAIT with attractive entry near $105 and trim above $135.

Thesis delta

The thesis is unchanged: MRK remains a WAIT. This licensing deal is a minor positive as it continues the strategy of acquiring oncology assets to offset Keytruda LOE, but it is not large enough to alter the earnings bridge. The fundamental challenges—Gardasil China weakness and the $2.5B 2026 headwind—persist.